Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund

Marker Therapeutics agreed to a $25 million stock purchase deal with Chicago-based institutional investor Lincoln Park Capital Fund to help advance clinical trials for some of its immunotherapy products.